A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Clinical trial NCT00550238 · COMPLETED
Trial details
- NCT number
- NCT00550238
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-07-01
- Primary completion
- 2018-05-30
- Enrollment
- 459
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.